	US 11,718,654 B2
	IL-2R-βγ binding compounds
William J. Dower, Menlo Park, CA (US); Michael C. Needels, Menlo Park, CA (US); Ronald W. Barrett, Menlo Park, CA (US); Alice V. Bakker, Menlo Park, CA (US); and Steven E. Cwirla, Menlo Park, CA (US)
Assigned to MEDIKINE, INC., Menlo Park, CA (US)
Filed by MEDIKINE, INC., Menlo Park, CA (US)
Filed on Nov. 4, 2020, as Appl. No. 17/89,515.
Claims priority of provisional application 62/930,758, filed on Nov. 5, 2019.
Prior Publication US 2021/0198336 A1, Jul. 1, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/55 (2006.01); C07K 16/30 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01)

CPC C07K 14/55 (2013.01) [C07K 16/30 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/92 (2013.01); C07K 2319/01 (2013.01); C07K 2319/30 (2013.01); C07K 2319/75 (2013.01)]

22 Claims

1. An IL-2Rβγc binding compound, wherein the IL-2Rβγc binding compound comprises an IL-2Rβγc ligand, wherein the IL-2Rβγc ligand comprises:

a ligand linker;

an IL-2Rβ ligand bound to the ligand linker, wherein the IL-2Rβ ligand comprises any one of SEQ ID NOS: 805-903, 911-913, 915-930, 2575-2655, 2661-2853, 2855-2891, 2900-2926, 2929-2939, 9301, and 9308; and

an IL-2Rγc ligand bound to the ligand linker, wherein the IL-2Rγc ligand comprises any one of SEQ ID NOS: 944-1028, 1032, 1034, 1042, 1044, 1051-1060, and 1601-1613.